Gain Therapeutics announced FDA authorization of its IND for GT-02287, enabling initiation of a Phase 2 Parkinson’s study.
Key Highlights:
- FDA has authorized the company’s IND for GT-02287, permitting Phase 2 clinical development in the U.S.
- Phase 2a oral study to enroll treated and untreated early Parkinson’s patients across U.S., Australia and Europe.
- Australian Phase 1a/1b sites are expected to join Phase 2 alongside new U.S. and select European centers.
- Company anticipates initiating the Phase 2 study in the third quarter of 2026.
Original SEC Filing:
This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.